Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT Study of Intravenous Exenatide in Healthy Volunteers
NCT02650479Phase 1Completed
- Sponsor
- Intarcia Therapeutics
- Start
- Jan 2016
- Primary completion
- Apr 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Intarcia Therapeutics. Primary endpoints: Mean Plasma Steady State Concentration of Exenatide at 35 days and Changes to QTc Interval Measurements at 56 days. Started Jan 2016; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02650479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650479.